FDA panel to consider KP.2 subvariant for updated vaccine

FDA staff recommends considering the KP.2 subvariant, now dominant in the U.S., for the next COVID vaccine. The advisory committee will vote on updating the vaccine formula for 2024-2025. Current vaccines show effectiveness against evolving strains, but waning over time. WHO advises a monovalent JN.1 lineage vaccine. FDA will consider recommendations for updated vaccines amid low uptake rates.